Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.46 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2608914 | 0.83 | SPR (0.61) | TAAR1CYP2D6CYP2C9CYP2C19KMT2A | |
| SCHEMBL1010819 | 0.83 | TAAR1 (0.62) | TAAR1CNR1NPC1RAB9AMTNR1A | |
| SCHEMBL22857525 | 0.82 | TAAR1 (0.57) | TAAR1CYP2D6CYP2C9CYP2C19KMT2A | |
| SCHEMBL26078968 | 0.82 | CYP2D6 (0.55) | CYP2D6CYP2C9CYP2C19KMT2ACNR1 | |
| SCHEMBL12862951 | 0.82 | SMN1; SMN2 (0.61) | TAAR1CYP2D6CYP2C9CYP2C19KMT2A | |
| SCHEMBL901955 | 0.81 | NPC1 (0.63) | TAAR1KMT2ACNR1NPC1RAB9A | |
| SCHEMBL7866857 | 0.80 | KMT2A (0.81) | CYP2D6CYP2C9CYP2C19KMT2ANPC1 | |
| SCHEMBL2016946 | 0.80 | TAAR1 (0.58) | TAAR1CNR1NPC1RAB9AMTNR1A | |
| SCHEMBL31173308 | 0.80 | MTNR1A (0.67) | TAAR1CNR1NPC1RAB9AMTNR1A | |
| Hydrochloric Acid SCHEMBL27729415 | 0.79 | KMT2A (0.78) | CYP2D6CYP2C9CYP2C19KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108463458-B | Modulators of ROR-gamma | 生命医药有限责任公司 | 2022-02-01 | — | — | CN | disclosed |
| US-11008340-B2 | Modulators of ROR-gamma | VITAE PHARMACEUTICALS, LLC (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3377482-B1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS LLC (US) | 2021-05-12 | — | — | EP | disclosed |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC (US) | 2019-10-24 | — | — | US | disclosed |
| EP-3377482-A1 | MODULATORS OF ROR-GAMMA | Vitae Pharmaceuticals, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| CN-108463458-A | MODULATORS OF ROR-GAMMA | 生命医药公司 | 2018-08-28 | — | — | CN | disclosed |
| EP-1276722-B1 | NAPHTHAMIDINE UROKINASE INHIBITORS | ABBOTT LAB (US) | 2006-03-08 | — | — | EP | disclosed |
| EP-1276722-A1 | NAPHTHAMIDINE UROKINASE INHIBITORS | Abbott Laboratories (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6504031-B1 | Enzyme inhibitor such as 6-(2-(1-isopropyl-1,2,3,4-tetrahydro -7-isoquinolinyl)ethenyl)-2-naphthalenecarboximidamide, used as angiogenesis inhibitors; antiarthritic, antiinflammatory and antitumor agents | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
| US-6495562-B1 | SUCH AS 6-(2-(4,4-DIETHYL-1-ISOPROPYL-3,4-DIHYDRO-6-ISOQUINOLINYL)CYCLOPROPYL)-2 -NAPHTHALENECARBOXIMIDAMIDE | ABBOTT LABORATORIES | 2002-12-17 | — | — | US | disclosed |
| WO-2001081314-A1 | NAPHTHAMIDINE UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008340-B2 | Modulators of ROR-gamma | RORC, RORB, RORA | TAAR1 1308/4885CYP2D6 626/4885CYP2C9 682/4885 |
| US-20190322687-A1 | MODULATORS OF ROR-GAMMA | RORC, RORB, RORA | TAAR1 1308/4885CYP2D6 626/4885CYP2C9 682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.